Intensity Therapeutics CEO Lewis Bender Receives 78,000-Share Option

What Happened
Lewis H. Bender, President, CEO and a director of Intensity Therapeutics, was granted a derivative award of 78,000 shares on July 16, 2026. The filing reports an acquisition price of $0.00 (derivative instrument) and a reported total immediate cash value of $0. This is a compensatory option award rather than an open-market purchase or sale.

Key Details

• Transaction date: July 16, 2026; Form 4 filed July 20, 2026 (filed within the two-business-day window).
• Instrument: Derivative option award for 78,000 shares; reported acquisition price $0.00.
• Shares owned after transaction: Not specified in the provided filing data.
• Footnote: The option “will vest, subject to the individual's continued service…, in four, equal, annual installments, beginning on July 16, 2026.”
• No 10b5-1, tax-withholding, or cashless-exercise language was reported in the provided details.

Context
This was a company-granted option award (compensation), not a market purchase or sale. The award vests over four equal annual installments starting July 16, 2026, per the footnote. Such awards are routine for executives and reflect compensation arrangements rather than an immediate investment decision by the insider.